Developer docs
API playgroundTry for free, no card

Search company profiles

Leukos Biotech

Full company profile

uuid0004jge

Namestring
Leukos Biotech
Legal namestring
Leukos Biotech, S. L.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Leukos Biotech, S.L. is a clinical-stage biopharmaceutical company headquartered in Barcelona, Spain, founded in 2015 as a spin-off of the Josep Carreras Leukaemia Research Institute. The company develops first-in-class therapeutics and companion diagnostics built on the serotonin receptor 1B (HTR1B) as a novel oncology target. Its lead asset AOP208 (formerly LB208) is an orally available, highly selective HTR1B antagonist that induces apoptosis and terminal differentiation in cancer stem cells while sparing healthy cells; the drug entered a Phase 1 trial (SERONCO-1) at VHIO in October 2024, with first patient dosed the same month. A secondary asset, LK-01 — a subcutaneous apomorphine formulation for Acute Myeloid Leukemia — received US FDA Orphan Drug Designation in June 2018. The company also holds proprietary monoclonal antibodies validated as biomarkers for HTR1B-based cancer diagnosis, prognosis, and patient stratification.

The underlying platform is anchored in research by co-founder and CSO Dr. Ruth M. Risueño, whose identification of HTR1B as a therapeutic target in leukemia was published in Nature's Leukemia journal in 2017 and patented. The pipeline spans hematological malignancies (AML, MDS) and selected solid tumors including triple-negative breast cancer, hepatocellular carcinoma, and ovarian cancer. Commercial development of AOP208 is led by Austrian partner AOP Health under a July 2022 licensing agreement, with Leukos retaining development and commercialization rights in certain territories.

Leukos Biotech's business model is licensing- and royalty-oriented: future commercial revenue is expected to flow from milestone payments and royalties under the AOP Health agreement, with current cash sourced primarily from public grants (CDTI, Spanish Ministry of Science and Innovation, Generalitat de Catalunya, ACCIÓ, EU Horizon 2020, ENISA) supplemented by venture equity from Inveready and CDTI Innvierte. The company had raised approximately €3.5M in seed funding by September 2016, runs a 1–10 employee operation, has no commercial product revenue, and operates a single Phase 1 program alongside preclinical biomarker and LK-01 development work.

Short descriptiontext

Leukos Biotech is a Barcelona-based clinical-stage biopharmaceutical spin-off developing first-in-class HTR1B antagonist oncology drugs (lead asset AOP208 in Phase 1) and companion diagnostic antibodies, targeting cancer stem cells in leukemia and solid tumors, with global development licensed to AOP Health.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology therapeutics development, biopharmaceutical drug discovery, cancer stem cell targeting, serotonin receptor antagonists, leukemia treatment research
Industry2 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Royalty Revenues
TypeLicensing Royalties
Description

Leukos Biotech generates revenue through licensing agreements with pharmaceutical partners. The company licensed LB208 to AOP Health, which committed to develop and commercialize the compound. Leukos retains development and commercialization rights in certain territories and receives milestone payments and royalties from the partnership.

leukosbiotech.com
2Grant Funding
TypeManaged Services
Description

The company has received public funding from multiple sources including CDTI, Ministerio de Ciencia e Innovación, Generalitat de Catalunya, ACCIÓ, European Union Horizon 2020 (SeroStrat project), and ENISA. Funding includes both grants and loans.

leukosbiotech.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Leukos Biotech develops first-in-class HTR1B (serotonin receptor 1B) antagonist drug candidates, with its lead compound LB208/AOP208 designed to target cancer stem cells and chemotherapy-resistant cells across hematological malignancies (AML, MDS) and solid tumors (TNBC, HCC, ovarian cancer). The company also develops proprietary monoclonal antibody biomarkers for patient stratification and a novel apomorphine formulation (LK-01) for Acute Myeloid Leukemia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • FDA Orphan Drug Designation granted for LK-01 in Acute Myeloid Leukemia
+2 more records
Product overview1 text field

Leukos Biotech is a biopharmaceutical company developing a portfolio of cancer therapeutics and diagnostic tools centered on the serotonin receptor 1B (HTR1B) target. The core product is LB208/AOP208, a first-in-class oral HTR1B antagonist with applications in both solid tumors and hematological malignancies. The company also developed LK-01, an Apomorphine-based formulation that received FDA Orphan Drug Designation for AML, and proprietary monoclonal antibodies (mABs) serving as biomarkers for cancer diagnosis and prognosis. All products are grounded in research from the Josep Carreras Leukaemia Research Institute.

Product and service3 records
1LB208 / AOP208
CategoryOncology drug candidate (small-molecule HTR1B antagonist)
Description

First-in-class, orally available, highly selective HTR1B (serotonin receptor 1B) antagonist drug candidate designed to treat hematological malignancies (Acute Myeloid Leukemia, Myelodysplastic Syndrome) and solid tumors (Triple Negative Breast Cancer, Hepatocellular Carcinoma, Ovarian Cancer) by targeting cancer stem cells and chemotherapy-resistant cells, inducing apoptosis and terminal differentiation while sparing healthy cells.

2LK-01 (Apomorphine formulation)
CategoryOncology drug candidate (Apomorphine-based formulation)
Description

Novel solid form of apomorphine administered as a subcutaneous injection that maintains clinically relevant plasma concentrations for several days; in development for the treatment of Acute Myeloid Leukemia and granted FDA Orphan Drug Designation.

3Proprietary HTR1B monoclonal antibody (mAB) biomarkers
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1AOP Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-01
Description

Partnership established in July 2022 for further development of Leukos Biotech's lead candidate LB208 (renamed AOP208). AOP Health, an Austrian pharmaceutical company specializing in rare diseases and critical care, leads and finances global clinical development. Leukos maintains development and commercialization rights in certain territories. Initial focus on hematology/oncology with potential to expand to other indications.

leukosbiotech.com
Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2018-06-07
Description

Swiss consulting company specializing in collaborations with start-ups and spin-offs. Provides regulatory strategy support for LK-01 US FDA regulatory activities, particularly for the Orphan Drug Designation program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leukos Biotech is a spin-off from the Josep Carreras Leukaemia Research Institute, established in 2015. The company holds a license from IJC covering proprietary use of drugs and antibodies developed by Dr. Risueño's team. IJC provides ongoing research support and access to scientific expertise.

4VHIO (Vall d'Hebron Instituto de Oncología)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partner in the consortium receiving €1.4M public funding. VHIO's UITM-CaixaResearch unit is conducting the SERONCO-1 Phase 1 clinical trial for AOP208. Dr. Irene Braña leads the trial at this single participating center.

leukosbiotech.com
5Leitat
Strategic tierSupportingTypeTechnology or Integration
Description

Consortium partner in the €1.4M public-private collaboration project. Leitat, a technology center in Catalonia, participates as a recipient of grant funding (as opposed to Leukos which receives a loan) for the project focused on advancing LB208 in precision oncology.

leukosbiotech.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Geron is a late-stage clinical biopharmaceutical company focused on hematologic malignancies, with approved drug Rytavels (imetelstat) for lower-risk MDS. Comparable emerging player developing oncology therapeutics targeting specific cancer cell biology (telomerase), with overlap in heme-malignancy focus.

TypeEmerging player
Description

Constellation Pharmaceuticals (acquired by MorphoSys in 2021) was a clinical-stage oncology company developing small molecule inhibitors of epigenetic regulators for heme malignancies and solid tumors. Comparable emerging player in small-molecule precision oncology for hematology indications.

3Forma Therapeutics
TypeEmerging player
Description

Forma Therapeutics (acquired by Novo Nordisk in 2022) was a clinical-stage biopharmaceutical company developing small molecule therapeutics for rare hematologic diseases and cancers, including sickle cell disease and AML. Highly comparable emerging player in hematology-focused small-molecule drug development.

TypeEmerging player
Description

MacroGenics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based therapeutics for cancer, with multiple oncology programs including MARGENZA. Adjacent emerging player developing innovative oncology biologics, paralleling Leukos's mAb biomarker-based approach.

TypeDirect peer
Description

Kura Oncology is a clinical-stage precision oncology company developing small molecule inhibitors for hematological malignancies (including AML with menin inhibitors) and solid tumors. Direct comparable to Leukos as a small-molecule heme-malignancy focused biotech at similar development stage.

TypeDirect peer
Description

Agios is a biopharmaceutical company focused on cellular metabolism and hematology/oncology therapeutics, with approved AML drug Tibsovo and a pipeline targeting MDS and rare hematologic disorders. Highly comparable commercial-stage adjacent peer in AML/MDS drug development.

TypeRegional player
Description

Ryvu Therapeutics is a Polish clinical-stage oncology biotech developing small molecule therapies in hematology and solid tumors. Comparable European regional peer for Leukos in early-stage small-molecule oncology drug discovery and development.

TypeBroad incumbent
Description

Incyte is a larger biopharmaceutical company with a strong oncology and hematology portfolio (Jakafi, Pemazyre, Opzelura) and a clinical pipeline addressing MDS, AML, and graft-versus-host disease. Broad incumbent in the same hematology/oncology competitive space where Leukos intends to position LB208/AOP208.

TypeDirect peer
Description

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics targeting the p53 pathway for hematological malignancies (MDS/AML). Compares directly to Leukos as a similarly sized, similarly staged oncology biotech pursuing a novel mechanism in AML/MDS with strategic licensing potential.

10AOP Health
TypeBroad incumbent
Description

AOP Health (AOP Orphan Pharmaceuticals) is an established Austrian specialty pharma company in rare diseases, critical care, and hematology/oncology. It is Leukos's licensing partner for LB208/AOP208 and a broader incumbent in the same therapeutic areas that comparably commercializes hematology/oncology drugs in Europe.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Leukos Biotech

Oncology Therapeuticsleukosbiotech.com

Leukos Biotech is a Barcelona-based clinical-stage biopharmaceutical spin-off developing first-in-class HTR1B antagonist oncology drugs (lead asset AOP208 in Phase 1) and companion diagnostic antibodies, targeting cancer stem cells in leukemia and solid tumors, with global development licensed to AOP Health.

What Leukos Biotech does

Leukos Biotech, S.L. is a clinical-stage biopharmaceutical company headquartered in Barcelona, Spain, founded in 2015 as a spin-off of the Josep Carreras Leukaemia Research Institute. The company develops first-in-class therapeutics and companion diagnostics built on the serotonin receptor 1B (HTR1B) as a novel oncology target. Its lead asset AOP208 (formerly LB208) is an orally available, highly selective HTR1B antagonist that induces apoptosis and terminal differentiation in cancer stem cells while sparing healthy cells; the drug entered a Phase 1 trial (SERONCO-1) at VHIO in October 2024, with first patient dosed the same month. A secondary asset, LK-01 — a subcutaneous apomorphine formulation for Acute Myeloid Leukemia — received US FDA Orphan Drug Designation in June 2018. The company also holds proprietary monoclonal antibodies validated as biomarkers for HTR1B-based cancer diagnosis, prognosis, and patient stratification.

The underlying platform is anchored in research by co-founder and CSO Dr. Ruth M. Risueño, whose identification of HTR1B as a therapeutic target in leukemia was published in Nature's Leukemia journal in 2017 and patented. The pipeline spans hematological malignancies (AML, MDS) and selected solid tumors including triple-negative breast cancer, hepatocellular carcinoma, and ovarian cancer. Commercial development of AOP208 is led by Austrian partner AOP Health under a July 2022 licensing agreement, with Leukos retaining development and commercialization rights in certain territories.

Leukos Biotech's business model is licensing- and royalty-oriented: future commercial revenue is expected to flow from milestone payments and royalties under the AOP Health agreement, with current cash sourced primarily from public grants (CDTI, Spanish Ministry of Science and Innovation, Generalitat de Catalunya, ACCIÓ, EU Horizon 2020, ENISA) supplemented by venture equity from Inveready and CDTI Innvierte. The company had raised approximately €3.5M in seed funding by September 2016, runs a 1–10 employee operation, has no commercial product revenue, and operates a single Phase 1 program alongside preclinical biomarker and LK-01 development work.

Leukos Biotech firmographics

Firmographics
Name
Leukos Biotech
Legal name
Leukos Biotech, S. L.
Website
https://leukosbiotech.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Leukos Biotech is a Barcelona-based clinical-stage biopharmaceutical spin-off developing first-in-class HTR1B antagonist oncology drugs (lead asset AOP208 in Phase 1) and companion diagnostic antibodies, targeting cancer stem cells in leukemia and solid tumors, with global development licensed to AOP Health.
Ownership category
akta.pro rank

Leukos Biotech industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Oncology therapeutics development
  • Biopharmaceutical drug discovery
  • Cancer stem cell targeting
  • Serotonin receptor antagonists
  • Leukemia treatment research

Where Leukos Biotech is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices1 record

Markets served

Leukos Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Royalty Revenues: Leukos Biotech generates revenue through licensing agreements with pharmaceutical partners. The company licensed LB208 to AOP Health, which committed to develop and commercialize the compound. Leukos retains development and commercialization rights in certain territories and receives milestone payments and royalties from the partnership.
  2. Grant Funding: The company has received public funding from multiple sources including CDTI, Ministerio de Ciencia e Innovación, Generalitat de Catalunya, ACCIÓ, European Union Horizon 2020 (SeroStrat project), and ENISA. Funding includes both grants and loans.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Leukos Biotech product offering

Product offering

Core offering

Leukos Biotech develops first-in-class HTR1B (serotonin receptor 1B) antagonist drug candidates, with its lead compound LB208/AOP208 designed to target cancer stem cells and chemotherapy-resistant cells across hematological malignancies (AML, MDS) and solid tumors (TNBC, HCC, ovarian cancer). The company also develops proprietary monoclonal antibody biomarkers for patient stratification and a novel apomorphine formulation (LK-01) for Acute Myeloid Leukemia.

Product overview

Leukos Biotech is a biopharmaceutical company developing a portfolio of cancer therapeutics and diagnostic tools centered on the serotonin receptor 1B (HTR1B) target. The core product is LB208/AOP208, a first-in-class oral HTR1B antagonist with applications in both solid tumors and hematological malignancies. The company also developed LK-01, an Apomorphine-based formulation that received FDA Orphan Drug Designation for AML, and proprietary monoclonal antibodies (mABs) serving as biomarkers for cancer diagnosis and prognosis. All products are grounded in research from the Josep Carreras Leukaemia Research Institute.

Differentiator

Problem solved

Functional benefit

Products and services

  • LB208 / AOP208 First-in-class, orally available, highly selective HTR1B (serotonin receptor 1B) antagonist drug candidate designed to treat hematological malignancies (Acute Myeloid Leukemia, Myelodysplastic Syndrome) and solid tumors (Triple Negative Breast Cancer, Hepatocellular Carcinoma, Ovarian Cancer) by targeting cancer stem cells and chemotherapy-resistant cells, inducing apoptosis and terminal differentiation while sparing healthy cells.
  • LK-01 (Apomorphine formulation) Novel solid form of apomorphine administered as a subcutaneous injection that maintains clinically relevant plasma concentrations for several days; in development for the treatment of Acute Myeloid Leukemia and granted FDA Orphan Drug Designation.
  • Proprietary HTR1B monoclonal antibody (mAB) biomarkers

Quantifiable outcome

  • FDA Orphan Drug Designation granted for LK-01 in Acute Myeloid Leukemia
  • +2 more outcomes

Companies that use Leukos Biotech

Customer profile

Segments2 records

Ideal customer profiles2 records

Leukos Biotech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Leukos Biotech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and supporting.

  • AOP HealthcoreStrategic or Co-development Partner · 1 July 2022Partnership established in July 2022 for further development of Leukos Biotech's lead candidate LB208 (renamed AOP208). AOP Health, an Austrian pharmaceutical company specializing in rare diseases and critical care, leads and finances global clinical development. Leukos maintains development and commercialization rights in certain territories. Initial focus on hematology/oncology with potential to expand to other indications.
  • Hemex AGsupportingImplementation/ SI/ Consulting Partner · 7 June 2018Swiss consulting company specializing in collaborations with start-ups and spin-offs. Provides regulatory strategy support for LK-01 US FDA regulatory activities, particularly for the Orphan Drug Designation program.
  • Josep Carreras Leukaemia Research Institute (IJC)coreStrategic or Co-development PartnerLeukos Biotech is a spin-off from the Josep Carreras Leukaemia Research Institute, established in 2015. The company holds a license from IJC covering proprietary use of drugs and antibodies developed by Dr. Risueño's team. IJC provides ongoing research support and access to scientific expertise.
  • VHIO (Vall d'Hebron Instituto de Oncología)coreStrategic or Co-development PartnerClinical trial partner in the consortium receiving €1.4M public funding. VHIO's UITM-CaixaResearch unit is conducting the SERONCO-1 Phase 1 clinical trial for AOP208. Dr. Irene Braña leads the trial at this single participating center.
  • LeitatsupportingTechnology or IntegrationConsortium partner in the €1.4M public-private collaboration project. Leitat, a technology center in Catalonia, participates as a recipient of grant funding (as opposed to Leukos which receives a loan) for the project focused on advancing LB208 in precision oncology.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Leukos Biotech competitors and assessment

Company assessment

Emerging players

  • Geron Corporation: Geron is a late-stage clinical biopharmaceutical company focused on hematologic malignancies, with approved drug Rytavels (imetelstat) for lower-risk MDS. Comparable emerging player developing oncology therapeutics targeting specific cancer cell biology (telomerase), with overlap in heme-malignancy focus.
  • Constellation Pharmaceuticals: Constellation Pharmaceuticals (acquired by MorphoSys in 2021) was a clinical-stage oncology company developing small molecule inhibitors of epigenetic regulators for heme malignancies and solid tumors. Comparable emerging player in small-molecule precision oncology for hematology indications.
  • Forma Therapeutics: Forma Therapeutics (acquired by Novo Nordisk in 2022) was a clinical-stage biopharmaceutical company developing small molecule therapeutics for rare hematologic diseases and cancers, including sickle cell disease and AML. Highly comparable emerging player in hematology-focused small-molecule drug development.
  • MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based therapeutics for cancer, with multiple oncology programs including MARGENZA. Adjacent emerging player developing innovative oncology biologics, paralleling Leukos's mAb biomarker-based approach.

Direct peers

  • Kura Oncology: Kura Oncology is a clinical-stage precision oncology company developing small molecule inhibitors for hematological malignancies (including AML with menin inhibitors) and solid tumors. Direct comparable to Leukos as a small-molecule heme-malignancy focused biotech at similar development stage.
  • Agios Pharmaceuticals: Agios is a biopharmaceutical company focused on cellular metabolism and hematology/oncology therapeutics, with approved AML drug Tibsovo and a pipeline targeting MDS and rare hematologic disorders. Highly comparable commercial-stage adjacent peer in AML/MDS drug development.
  • Aprea Therapeutics: Aprea Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics targeting the p53 pathway for hematological malignancies (MDS/AML). Compares directly to Leukos as a similarly sized, similarly staged oncology biotech pursuing a novel mechanism in AML/MDS with strategic licensing potential.

Regional players

  • Ryvu Therapeutics: Ryvu Therapeutics is a Polish clinical-stage oncology biotech developing small molecule therapies in hematology and solid tumors. Comparable European regional peer for Leukos in early-stage small-molecule oncology drug discovery and development.

Broad incumbents

  • Incyte Corporation: Incyte is a larger biopharmaceutical company with a strong oncology and hematology portfolio (Jakafi, Pemazyre, Opzelura) and a clinical pipeline addressing MDS, AML, and graft-versus-host disease. Broad incumbent in the same hematology/oncology competitive space where Leukos intends to position LB208/AOP208.
  • AOP Health: AOP Health (AOP Orphan Pharmaceuticals) is an established Austrian specialty pharma company in rare diseases, critical care, and hematology/oncology. It is Leukos's licensing partner for LB208/AOP208 and a broader incumbent in the same therapeutic areas that comparably commercializes hematology/oncology drugs in Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Leukos Biotech social profiles

Digital presence

Leukos Biotech compliance and trust

Trust signal

Compliance2 records

Leukos Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Leukos Biotech leadership team

Management profile

Number of profiles

Profiles2 records

Leukos Biotech funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Leukos Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leukos Biotech

What does Leukos Biotech do?

Leukos Biotech develops first-in-class HTR1B (serotonin receptor 1B) antagonist drug candidates, with its lead compound LB208/AOP208 designed to target cancer stem cells and chemotherapy-resistant cells across hematological malignancies (AML, MDS) and solid tumors (TNBC, HCC, ovarian cancer). The company also develops proprietary monoclonal antibody biomarkers for patient stratification and a novel apomorphine formulation (LK-01) for Acute Myeloid Leukemia.

Is Leukos Biotech a public or private company?

Leukos Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Leukos Biotech founded?

Leukos Biotech was founded in 2015. It employs 1 to 10 people.

Where is Leukos Biotech based?

Leukos Biotech is headquartered in Barcelona, Spain, in the Europe region.

How does Leukos Biotech make money?

Two revenue lines are on record. Licensing and Royalty Revenues are the primary driver. The others are grant Funding.

Who are Leukos Biotech's main competitors?

Emerging players on record are Geron Corporation, Constellation Pharmaceuticals, Forma Therapeutics and MacroGenics. Direct peers are Kura Oncology, Agios Pharmaceuticals and Aprea Therapeutics. Ryvu Therapeutics is listed as a regional player. Broad incumbents are Incyte Corporation and AOP Health.

Does Leukos Biotech have an API?

No public API is recorded for Leukos Biotech.

What industry is Leukos Biotech in?

Leukos Biotech's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals